特利加压素治疗肝肾综合征有效性及安全性的Meta分析

Efficacy and safety of terlipressin in treatment of patients with hepatorenal syndrome:A Meta-analysis

目的评价特利加压素治疗肝肾综合征(HRS)的有效性及安全性。方法采用Cochrane系统评价方法,计算机检索MEDLINE,PubMed,Embase,Medline,Cochrane Library及Google(TM)Scholar databases,检索时间截止至2012年4月公开发表的随机对照临床试验。根据纳入与排除标准筛选文献、评价文献质量、提取资料,采用RevMan 5.1软件进行Meta分析。结果在47篇文献中纳入4篇文献,包括了234例HRS患者。文献的Cochrane质量评价均为B级,均属于较高质量文献。Meta分析结果显示,特利加压素治疗HRS的有效率为47%,明显高于对照组的11.9%(P<0.00001)。结论特利加压素可显著提高HRS患者肾小球滤过率,降低肌酐水平,改善肾脏功能。

Objective To evaluate the efficacy and safety of terlipressin in treatment of patients with hep- atorenal syndrome（HRS）. Methods We searched MEDLINE,PubMed,EMbase,Cochrane Library and Google（TM） Scholar databases to collect randomized controlled trials （RCT）of tedipressin in treatment of patients with HRS, which were published before April,2012. We selected the retrieved studies according to the predefined inclusion and exclusion criteria,evaluated the quality of included studies,and performed Meta-analyses using the Cochrane Collaboration＇s RevMan 5.1 software. Result Four RCTs out of 47 papers involving 234 patients with HRS were included. All included trims were of quality B. Meta-analysis showed that the effective rate in terlipressin group was significantly higher than in control group [47% vs. 11.9%,OR=3.S1,95%CI（3.17,17.59）,P〈0.00001]. Conclusion Terlipressin can increase glomerular filtration rate,decrease ereatinine levels and improve the kidney function in the patients with HRS.